Shattuck Labs (STTK) AI Stock Analysis

• Market Cap: $94.85M
• Dividend Yield: N/A
• Average Volume (3M): 4.41M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.98
• Revenue Growth: -27.33%
• EPS Growth: 34.66%
• Country: US
• Employees: 44
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -0.24
• Shares Outstanding: 47,903,214
• 10 Day Avg. Volume: 2,516,146
• 30 Day Avg. Volume: 4,409,645
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.07
• Enterprise Value/Revenue: -0.19
• Enterprise Value/Gross Profit: -0.48
• Enterprise Value/Ebitda: 0.11
• 1Y Price Target: $3.00
• Price Target Upside: 51.52% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

• Rating: 55 Neutral
• Price Target: $1.50 ▼(-24.24% Downside)

The overall stock score is primarily influenced by the company's financial challenges and negative valuation metrics. However, positive technical indicators and significant corporate events, such as the recent private placement funding, provide some optimism for future growth. The stock's mixed technical signals and reliance on external financing are key risks to consider.

Positive Factors

Strategic Repositioning

The strategic shift towards immunology and inflammation, supported by new board members, enhances Shattuck Labs' focus and potential in addressing unmet medical needs, potentially leading to stronger market positioning and improved patient outcomes.

Strong Cash Position

A strong cash position provides Shattuck Labs with the financial flexibility to fund its R&D activities and clinical trials, reducing the immediate need for external financing and supporting long-term operational stability.

Private Placement Funding

The $103 million funding from the private placement secures financial resources for Shattuck Labs to advance its clinical programs, potentially leading to successful product developments and future revenue streams.

Negative Factors

Declining Revenue

The decline in revenue growth indicates challenges in commercializing products and generating consistent income, which could impact long-term sustainability and the ability to invest in future R&D.

Negative Profitability

Persistent negative profitability highlights operational inefficiencies and the need for cost management, which could hinder Shattuck Labs' ability to achieve financial independence and fund future growth.

Reliance on External Financing

Heavy reliance on external financing indicates potential vulnerability to market conditions and investor sentiment, which could affect the company's ability to sustain operations and fund new initiatives without consistent internal cash generation.

Shattuck Labs Business Overview & Revenue Model

Company Description

Shattuck Labs (STTK) is a clinical-stage biotechnology company that focuses on developing novel therapeutics for the treatment of cancer and autoimmune diseases. The company specializes in its proprietary ARC (Agonist Redirected Checkpoint) platform, which is designed to create dual-function fusion proteins that modulate immune responses. Shattuck Labs operates within the biotechnology and pharmaceutical sectors, aiming to address unmet medical needs through innovative biological therapies.

How the Company Makes Money

Shattuck Labs makes money primarily through the development and eventual commercialization of its therapeutic products. The company generates revenue through partnerships and collaborations with other pharmaceutical companies, which may include licensing agreements, milestone payments, and royalties. Additionally, as its therapies progress through clinical trials and receive regulatory approval, Shattuck Labs anticipates earning revenue from product sales. The company's ability to secure funding through investments and grants also supports its research and development activities, contributing to its financial stability.

Shattuck Labs Financial Statement Overview

Summary

Shattuck Labs faces significant financial challenges with declining revenues, negative profitability, and operational inefficiencies. While the company maintains a strong cash position, it relies heavily on external financing. The biotechnology industry often involves high R&D costs, contributing to losses. Continued focus on revenue growth and managing operational costs is essential for improving financial health.

Income Statement

The company shows a significant decline in revenue growth over the years, with TTM revenue at $19.1 million compared to $30 million in 2021. Gross profit margin is negative, indicating high operating costs. Net profit margin remains negative, reflecting ongoing losses. EBIT and EBITDA margins are also negative, highlighting operational inefficiencies and a lack of profitability.

Balance Sheet

The debt-to-equity ratio is low due to minimal debt, which is a positive aspect. However, the equity ratio has decreased over time, indicating a decline in financial stability. Return on equity is negative, reflecting persistent losses. The company maintains a strong cash position, although total assets have decreased, indicating potential liquidity concerns.

Cash Flow

The operating cash flow to net income ratio is negative, reflecting cash outflows from operations. Free cash flow has improved slightly but remains negative, indicating an inability to generate sufficient cash to cover expenses. Positive financing cash flow suggests reliance on external funding to support operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	37.70M	5.72M	1.66M	652.00K	30.02M	9.93M
Gross Profit	14.67M	1.89M	-2.38M	-2.72M	28.64M	-27.55M
EBITDA	-62.15M	-76.74M	-87.92M	-100.26M	-43.89M	-36.31M
Net Income	-61.51M	-75.41M	-87.30M	-101.94M	-44.97M	-36.60M
Balance Sheet
Total Assets	64.37M	91.05M	159.56M	205.32M	298.58M	348.99M
Cash, Cash Equivalents and Short-Term Investments	50.47M	72.99M	130.63M	161.28M	268.80M	335.45M
Total Debt	2.02M	3.41M	4.20M	4.90M	0.00	0.00
Total Liabilities	7.35M	11.42M	14.86M	29.17M	26.80M	39.13M
Stockholders Equity	57.02M	79.63M	144.71M	176.16M	271.79M	309.86M
Cash Flow
Free Cash Flow	-55.94M	-60.57M	-81.64M	-106.11M	-65.04M	-34.39M
Operating Cash Flow	-55.90M	-60.52M	-81.23M	-94.50M	-57.12M	-33.66M
Investing Cash Flow	45.78M	-8.51M	110.86M	49.44M	-10.44M	-146.32M
Financing Cash Flow	-106.00K	787.00K	48.62M	171.00K	1.93M	330.87M

Shattuck Labs Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.98
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STTK, the sentiment is Positive. The current price of 1.98 is above the 20-day moving average (MA) of 1.24, above the 50-day MA of 0.98, and above the 200-day MA of 1.07, indicating a bullish trend. The MACD of 0.26 indicates Negative momentum. The RSI at 75.02 is Negative, neither overbought nor oversold. The STOCH value of 88.15 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STTK.

Shattuck Labs Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STTK	55 Neutral	$94.85M	―	-73.39%	―	-27.33%	34.66%
XLO	54 Neutral	$37.82M	―	-277.74%	―	536.44%	63.68%
Sector *	51 Neutral	$8.02B	-0.39	-43.38%	2.20%	22.34%	-2.13%
PYPD	41 Neutral	$35.16M	―	-312.77%	―	―	61.18%
COEP	―	$59.92M	―	-171.56%	―	―	―
LVTX	47 Neutral	$41.17M	―	-90.07%	―	-32.55%	-15.83%
ACRV	36 Underperform	$48.76M	―	-47.87%	―	―	18.86%

Shattuck Labs Corporate Events

Shattuck Labs Closes $103M Private Placement Deal

On August 26, 2025, Shattuck Labs announced the closing of a private placement of up to $103 million, led by OrbiMed, which is expected to fund operations into 2029 and advance their lead program, SL-325, through multiple clinical milestones. The company also appointed Dr. Daniel Baker and Dr. Mona Ashiya to its Board of Directors, marking a strategic repositioning towards an immunology and inflammation-focused organization. These developments are significant as they aim to enhance Shattuck’s industry positioning and potentially improve outcomes for patients with immune-mediated diseases.

Shattuck Labs Announces $103M Private Placement Funding

On August 5, 2025, Shattuck Labs announced an oversubscribed private placement expected to raise up to approximately $103 million, led by OrbiMed and other investors. The funds will support the clinical development of SL-325 through multiple Phase 2 trials for inflammatory bowel disease and potentially other autoimmune diseases, with operations funded into 2029. The private placement involves shares of common stock and pre-funded warrants, with the proceeds contingent on certain regulatory clearances and conditions.

Shattuck Labs Elects Directors, Approves Auditor at Meeting

On July 10, 2025, Shattuck Labs, Inc. held its Annual Meeting of Stockholders where all director nominees were elected and the proposal to ratify KPMG LLP as the independent auditor was approved. The meeting involved voting on the election of Class II Director Nominees and the ratification of KPMG LLP, reflecting shareholder support for the company’s governance and financial oversight.